We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CTMX market cap is 66.52M. The company's latest EPS is USD -0.0073 and P/E is -116.44.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.38M | 26.61M | 41.46M | 25.12M | 33.43M |
| Operating Income | 3.12M | -606k | 11.66M | -8.45M | 4.11M |
| Net Income | 2.99M | 837k | 13.79M | -6.53M | 5.74M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 57.49M | 100.36M | 69.57M | 53.16M | 101.21M |
| Operating Income | -110.9M | -48.61M | -83.78M | -101.34M | -6.48M |
| Net Income | -102.24M | -32.89M | -83.61M | -99.32M | -569k |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 221.17M | 201.79M | 184.69M | 159.22M | 138.98M |
| Total Liabilities | 272.41M | 249.24M | 216.37M | 190.45M | 162.43M |
| Total Equity | -51.24M | -47.45M | -31.68M | -31.23M | -23.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 341.28M | 358.66M | 339.41M | 260.89M | 201.79M |
| Total Liabilities | 290.17M | 308.86M | 250.03M | 346.64M | 249.24M |
| Total Equity | 51.11M | 49.8M | 89.38M | -85.75M | -47.45M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -34.07M | -56.04M | -26.05M | -45.59M | -66.32M |
| Investing | -163.54M | -150.67M | 44.89M | 66.4M | 84.57M |
| Financing | 29.99M | 30.23M | 174k | 5.27M | 5.27M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -140.48M | 5.26M | -119.03M | -110.79M | -56.04M |
| Investing | 79.7M | -18.72M | 22.49M | 98.26M | -150.67M |
| Financing | 1.63M | 16.89M | 110.21M | 648k | 30.23M |
| Market Cap | 66.52M |
| Price to Earnings Ratio | -116.44 |
| Price to Sales Ratio | 0.66 |
| Price to Cash Ratio | 3.87 |
| Price to Book Ratio | -1.4 |
| Dividend Yield | - |
| Shares Outstanding | 78.26M |
| Average Volume (1 week) | 777.32k |
| Average Volume (1 Month) | 1.07M |
| 52 Week Change | -42.57% |
| 52 Week High | 5.85 |
| 52 Week Low | 0.79 |
| Spread (Intraday) | 0.04 (4.12%) |
| Company Name | CytomX Therapeutics Inc |
| Address |
850 new burton road dover, delaware 19904 |
| Website | https://www.cytomx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
